SCHEMBL6315313

SCHEMBL6315313

COc1ccc(OC)c(C(=O)C2CCC2c2ccc(OC)c(OOP(=O)(O)O)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 2/20 0.41
KDM1A O60341 2/20 0.39
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ALDH1A1 P00352 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALOX15 P16050 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
POLB P06746 1/20 0.36
MTNR1A P48039 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6314633 0.94 KDM1A (0.40) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6314453 0.94 MAPT (0.43) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6315331 0.93 MAPT (0.38) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6316452 0.93 MAPT (0.39) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6322855 0.93 MAPT (0.39) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6315408 0.91 MAPT (0.38) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6316373 0.90 MAPT (0.37) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6316369 0.88 MAPT (0.37) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6323423 0.87 KDM1A (0.38) MAPTKDM4ELMNAKDM1AHTT
SCHEMBL6313897 0.87 KDM1A (0.38) MAPTKDM4ELMNAKDM1AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887904-B2 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S. A. (FR) 2005-05-03 US disclosed
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof AVENTIS PHARMA S.A. (FR) 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149072-A1 Substituted arylcycloalkanes, compositions containing them and use thereof ABL1, MCL1, AHR MAPT 4538/4885KDM4E 1243/4885LMNA 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.